Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026
The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.
Source: www.fool.com
The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.